CQSP in Malawi: Chloroquine and Sulfadoxine-pyrimethamine Efficacy for the Treatment of Malaria in Malawi
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to find out how well chloroquine works as a drug to
treat malaria in children, compared to the standard malaria treatment in Malawi. In
preparation for a longer study of the malaria treatment medication chloroquine alone and in
combination with other drugs, a shorter pre-study will be done to compare the anti-malarial
effectiveness of chloroquine versus sulfadoxine-pyrimethamine (SP), the standard treatment in
Malawi. Two hundred ten children, ages 6 months to 12 years, around Blantyre, Malawi, will be
given standard dosing of either chloroquine or SP when they come to the Ndirande Health
Centre with signs or symptoms consistent with malaria. The first 30 participants in each
treatment group will remain under continuous observation at the health center so that the
researchers can monitor their response to the medication until the infection goes away. The
participants will be followed for 28 days to see if the the treatment works or fails.
Phase:
Phase 4
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Treatments:
Chloroquine Chloroquine diphosphate Fanasil, pyrimethamine drug combination Pyrimethamine Sulfadoxine